Listed

DENTSPLY SIRONA Inc.: Form 10-Q for the period ended Mar 31, 2025

Filed with the SEC on May 8, 2025 and accepted by EDGAR at May 8, 2025, 09:13 ET.

Share

Management's discussion and analysis

As filed, 46,372 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Information included in or incorporated by reference in this Form 10-Q, and other filings with the SEC and the Company’s press releases or other public statements, contains or may contain forward-looking statements. Please refer to the discussion under the header “Forward-Looking Statements and Associated Risks” in the forepart of this Form 10-Q.

Company Profile

DENTSPLY SIRONA Inc. is the world’s largest diversified manufacturer of professional dental products and technologies, with a 138-year history of innovation and service to the dental industry, and a vision of improving oral health and continence care globally. Dentsply Sirona develops, manufactures, and markets comprehensive solutions, including technologically advanced dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective, and connected solutions to advance patient care and deliver better, safer, and faster dentistry. Dentsply Sirona’s worldwide headquarters is located in Charlotte, North Carolina, and its shares of common stock are listed in the United States on Nasdaq under the symbol XRAY.

BUSINESS

Segment Descriptions

A description of the products and services provided within each of the Company’s four reportable segments is provided below.

Connected Technology Solutions

This segment includes the design, manufacture, and sales of the Company’s dental technology and equipment products. These products include the Equipment & Instruments and CAD/CAM product categories. Dental CAD/CAM technologies are products designed for dental professionals to support numerous digital workflows for procedures such as dental restorations through integrations with DS Core, our cloud-based platform.

Essential Dental Solutions

This segment includes the development, manufacture, and sales of the Company’s value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Offerings in this segment also include specialized treatment products including products used in the creation of dental appliances.

Orthodontic and Implant Solutions

This segment includes the design, manufacture, and sales of the Company’s various digital implant systems and innovative dental implant products, digital dentures and dental professional-directed aligner solutions. Offerings in this segment also include application of our digital services and technology, including those provided by DS Core, our cloud-based platform.

Wellspect Healthcare

This segment includes the design, manufacture, and sales of the Company’s innovative continence care solutions for both urinary and bowel management. Wellspect is one of the world’s leading manufacturers of intermittent urinary catheters, with LoFric as its most known brand. To help those with chronic or severe constipation, Wellspect also offers an advanced irrigation system, Navina, which combines a high degree of user convenience, clinical effectiveness and connectivity into one smart system.

The impact of global economic conditions

Various headwinds are expected to weigh on global growth throughout the remainder of 2025, due in large part to increasing uncertainties related to global trade policy and inflation. A number of key macroeconomic forecasts were sharply lowered in April 2025 in response to the potential for a severe escalation in global trade barriers and competition. Weaker overall growth in the United States and narrowing interest rate differentials suggest the potential for further depreciation of the U.S. dollar and heightened risk of recession. Markets in several other regions, including Europe, have continued to experience varying degrees of pressures inhibiting growth and face concerns about the systemic impacts of adverse economic conditions and geopolitical events. Changes in trade policy, supply chain constraints, higher energy costs, labor shortages, and geopolitical tensions in the Middle East and Ukraine have all contributed to the risk of higher inflation and general economic uncertainty across the industry and the regions in which the Company operates. In recent years the Company has experienced higher prices for certain raw materials, including electronic components, which have led to a negative impact on margins. Although the rate of inflation showed signs of slowing at the start of 2025, prices for both raw materials and wages are expected to remain high through the remainder of the year, and prices may potentially increase if trade conflicts deepen. The Company may not be successful in its efforts to fully mitigate or offset the impacts of cost inflation.

The challenging macroeconomic conditions have also negatively impacted demand for the Company’s products and may continue to do so in the future. These conditions include a steep decline in measures of consumer confidence in the United States since the start of the year. Additionally, higher interest rates have put pressure on the ability and willingness of our customers to obtain financing for equipment purchases, which adversely affects volumes for these products. The higher cost of borrowing has also reduced patient demand for elective dental procedures, which affects sales of the Company’s offerings more broadly. The Company has also faced additional competitive pressure from dental practices for lower-priced options for equipment and other products, in particular imaging products and implants. While the Company has taken steps to address competitive pressures, such as the reintroduction of its Orthophos SL 2D and 3D products, these trends may continue. While patient volumes have largely remained stable in the United States, the impact of macroeconomic declines and high interest rates has been particularly apparent in Germany, which represented 11% of the Company’s sales for the three months ended March 31, 2025. Germany was in a recession for most of 2023, largely due to persistent high inflation and falling household spending. Although conditions, including inflation, marginally improved in 2024, economic forecasts by the German government project limited growth in 2025. The Company anticipates that the challenging macroeconomic and market conditions in Germany are likely to persist and may negatively impact sales of equipment in 2025, despite moderate growth in the first quarter.

In anticipation of a continued inflationary trend and potentially deteriorating macroeconomic environment, we have attempted to mitigate these pressures through the following actions, among others:

  • Driving strategic procurement initiatives to leverage alternative sources of raw materials and transportation;
  • Implementing cost-containment measures, as well as intensifying continuous improvement and restructuring programs in our manufacturing and distribution facilities and other areas of our business, including the most recent restructuring plan approved by our Board of Directors on July 29, 2024;
  • Optimizing our customer management and implementing strategic investments in our commercial sales organization in key markets, particularly the United States; and
  • Refining our focus on developing a winning portfolio with global scale to maximize market share in a competitive pricing environment.

Recent tariff policies

As disclosed in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”), the Company’s business is subject to risks related to, among other factors, tariffs and other trade protection measures put in the place by the United States and other countries. The U.S. government has recently implemented or is in the process of implementing various tariffs on the importation of goods from certain countries, a number of which are applicable to the Company’s supply chain, operations, and sales. On April 2, 2025, the United States announced a baseline 10% tariff on all foreign goods and incremental tariff rates on goods imported from specified nations, including China and those in the European Union. The announced tariffs incremental to the baseline were subsequently suspended for a period of 90 days; however, China’s tariff rate was raised to 145%.

The tariffs enacted and proposed by the Trump Administration to date and retaliatory tariffs by other countries could make it significantly more difficult or costly for the Company to import certain products or materials to the United States, or export products or materials from the United States to other countries. Currently, a small portion of the products, materials, and components used in our products are imported from China, and a significant share of the dental equipment that we sell in the United States is manufactured in Europe. Europe is also a major market for our products, while sales in China represent less than 5% of the Company’s global sales on an annual basis. If the United States’ previously announced incremental tariffs imposed on member states of the European Union go into effect, or if member states of the European Union subsequently impose retaliatory tariffs on the United States, there may be a material impact on our business and results of operations. We continue to monitor and evaluate the ongoing and potential impacts of the tariffs and changes in trade policy, whether implemented or proposed, on our supply chain, costs, sales and profitability. We seek to implement strategies that would mitigate such impacts, including by reviewing competitive pricing strategies to offset tariffs and evaluating potential sourcing options that work with our vendors and merchants to seek to minimize products sourced from high tariff rate countries, both for existing products and for new product development. The impact that these tariffs and changes in trade policy will ultimately have on our financial results remains unclear, including the impact on demand for our products in certain markets if prices rise as a consequence of import tariffs. For additional information, see Part I, Item 1A, “Risk Factors” in our 2024 Form 10-K.

The impact of geopolitical conflicts

In 2025, geopolitical conflicts are expected to continue to shape market dynamics and pose general threats to financial stability in affected regions, including ongoing tensions from the Russia-Ukraine conflict and the conflict in the Middle East. Overall, the Company’s operations in Russia, Ukraine, and Israel have not been materially impacted by these conflicts.

The Company’s operations in Israel consist of two manufacturing facilities for implants products, with one site in northern Israel and one site in southern Israel, both of which remain open and continue to operate normally. For the three months ended March 31, 2025, net sales of products produced at these sites comprised approximately 4% of our consolidated net sales and 15% of the net sales of the Orthodontic and Implant Solutions segment. Net assets within Israel totaled $153 million as of March 31, 2025, consisting primarily of acquired technology, property, plant and equipment, inventory, and cash associated with our operations in the country.

In May 2024, in response to ongoing military actions by Israel in the Gaza strip, the government of Turkey implemented restrictions on the import of goods manufactured within Israel for sale in the Turkish market, which were still in effect as of March 31, 2025. Sales of our products made in Israel and sold in Turkey have historically represented approximately 1% of our global sales of the Implant & Prosthetic Solutions reporting unit, but this product category is an area of relatively high potential growth. The loss of sales to Turkey in 2024 was partially offset by sales of implants produced outside of Israel. It is not clear when these restrictions will be lifted or if other countries will institute similar restrictions.

In February 2022, because of the invasion of Ukraine by Russia, economic sanctions were imposed by the United States, the European Union, and certain other countries on Russian financial institutions and businesses. Due to the medical nature of our products, the current sanctions have not materially restricted our ability to continue selling many of our products to customers located in Russia. For the three months ended March 31, 2025, net sales in Russia and Ukraine were approximately 2% of our consolidated net sales, and net assets in these countries were $87 million as of March 31, 2025. These net assets include $49 million of cash and cash equivalents held within Russia as of March 31, 2025, as well as inventory and trade accounts receivable. Due to currency control measures imposed by the Russian government, which include restrictions on the ability of companies to repatriate or otherwise remit cash from their Russian-based operations to locations outside of Russia, we continue to be limited in our ability to transfer this cash balance out of Russia without incurring substantial costs. Additionally, beginning in September 2024, as a result of further restrictions by European financial institutions on receiving payments from Russia, our capacity to receive intercompany payments for the delivery of our products into Russia has been partially reduced, which further limits our ability to use cash received from sales in Russia for our general purposes. It is unclear whether the remaining financial institutions which the Company relies upon for bank transfers from Russia will ultimately be able to continue facilitating payments, or for how long. If these restrictions on cash transfers from Russia worsen, or if we are not able to obtain long-term relief from these restrictions, we may need to take additional actions, including potential suspension of our business in Russia.

Distribution arrangements

In July 2024, the Company delivered a one-year notice of non-renewal in connection with its non-exclusive distribution agreements with Patterson Companies, Inc. (“Patterson”) for the distribution of dental equipment in the United States and Canada. It is anticipated that Patterson will continue to be one of the Company’s two largest distributors as a percentage of the Company’s global revenue during the one-year notice period. The Company intends to continue to engage in discussions for new distribution agreements with Patterson. However, failure to successfully renegotiate the distribution agreements or secure potential new agreements with another distributor could have a material adverse effect on the Company’s business, operating results and financial condition. The Company has not incurred any charges against earnings to date related to non-renewal of the distribution agreements. For additional information, see Part I, Item 1A, “Risk Factors” in our 2024 Form 10-K.

RESULTS OF OPERATIONS, THREE MONTHS ENDED MARCH 31, 2025 COMPARED TO THREE MONTHS ENDED MARCH 31, 2024

Net Sales

The Company presents net sales comparing the current year periods to the prior year periods. In addition, the Company also presents changes in net sales on an organic sales basis, which is a Non-GAAP measure. The Company defines “organic sales” as the reported net sales adjusted for: (1) net sales from acquired and divested businesses recorded prior to the first anniversary of the acquisition or divestiture; (2) net sales attributable to discontinued product lines in both the current and prior year periods; and (3) the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period’s currency exchange rates.

Our measure of organic sales may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. Organic sales is an important internal measure for the Company, and its senior management receives a monthly analysis of operating results that includes organic sales. The performance of the Company is measured on this metric along with other performance metrics.

The Company discloses changes in organic sales to allow investors to evaluate the performance of the Company’s operations exclusive of the items listed above that may impact the comparability of results from period to period and may not be indicative of past or future performance of the normal operations of the Company. The Company believes that this supplemental information is helpful in understanding underlying net sales trends.

A reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Net sales $879 $953 $(74) (7.7%)
Unfavorable foreign exchange impact (3.3%)
Organic sales (4.4%)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was driven by lower volumes in the Orthodontic and Implant Solutions segment as a result of the suspension of the sale and marketing of Byte aligner system and impression kits announced in October 2024, as well as lower volumes of implants and prosthetics products across all regions. These decreases were partially offset by growth in the Wellspect Healthcare segment.

Net Sales by Segment

Connected Technology Solutions

A reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Net sales $235 $247 $(12) (4.7%)
Unfavorable foreign exchange impact (4.2%)
Organic sales (0.5%)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily due to lower volumes of CAD/CAM products across all three regions, driven in part by lower demand and competitive pressures including pricing. The decrease was partially offset by higher volumes of imaging products across all three regions, as well as higher sales of treatment centers, which was primarily due to the timing of fulfilling a one-time order in Europe during the quarter.

Essential Dental Solutions

A reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Net sales $353 $364 $(11) (2.7%)
Unfavorable foreign exchange impact (3.1%)
Organic sales 0.4%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was driven by growth in Europe and Rest of World, in part due to favorable pricing of restorative products, partially offset by lower volumes of endodontic and restorative products in the United States.

Orthodontic and Implant Solutions

A reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Net sales $217 $271 $(54) (20.0%)
Unfavorable foreign exchange impact (2.3%)
Organic sales (17.7%)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily driven by weaker sales of aligners in the United States, which were negatively impacted by the suspension of the sale and marketing of Byte aligner system and impression kits announced in October 2024, as well as a decrease in volume for implants and prosthetics products across all three regions. The decrease was partially offset by higher volumes of orthodontic products in Europe. Additionally, during the three months ended March 31, 2025, the Company refined its estimate of expected customer refunds for the Byte aligner business, resulting in an $8 million favorable adjustment to net sales.

Wellspect Healthcare

A reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Net sales $74 $71 $3 3.4%
Unfavorable foreign exchange impact (4.6%)
Organic sales 8.0%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was due to higher volumes across all regions, particularly in Europe and the United States, driven in part by new product launches.

Net Sales by Region

United States

A reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Net sales $302 $356 $(54) (15.2%)
Unfavorable foreign exchange impact (0.3%)
Organic sales (14.9%)

Percentages are based on actual values and may not reconcile due to rounding.

The decrease in organic sales was primarily due to the suspension of the sale and marketing of Byte aligner system and impression kits announced in October 2024. The decrease was also due to lower volumes for CAD/CAM equipment, implants products, and endodontic and restorative products. These decreases were partially offset by higher volumes for preventive products, imaging equipment, and Wellspect Healthcare products.

Organic sales of CAD/CAM were negatively affected by wholesale volumes for CAD/CAM products relative to the three months ended March 31, 2024 due in part to timing of distributor orders. Volumes for CAD/CAM products during the three months ended March 31, 2025 included a seasonal build of inventory held by distributors of approximately $4 million compared to a higher build of approximately $9 million for the three months ended March 31, 2024.

Volumes for imaging products in the three months ended March 31, 2025 were positively impacted by a build in distributor inventory of approximately $6 million, compared to a decrease of approximately $7 million in the three months ended March 31, 2024, while retail sales during the quarter were comparatively lower.

Distributor inventory levels for both CAD/CAM and imaging products at March 31, 2025 approximate historical averages.

Europe

A reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Net sales $362 $376 $(14) (3.4%)
Unfavorable foreign exchange impact (4.5%)
Organic sales 1.1%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was primarily due to higher volumes of imaging equipment and treatment centers within the Connected Technology Solutions segment, higher volumes and favorable pricing of restorative products in the Essential Dental Solutions segment, and higher volumes in the Wellspect Healthcare business, primarily driven by new product launches. These increases were partially offset by lower volumes of CAD/CAM equipment and implants and prosthetics products.

Rest of World

A reconciliation of net sales to organic sales is as follows:

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Net sales $215 $221 $(6) (2.8%)
Unfavorable foreign exchange impact (5.9%)
Organic sales 3.1%

Percentages are based on actual values and may not reconcile due to rounding.

The increase in organic sales was primarily driven by higher volumes of treatment center and imaging products and growth in the Wellspect Healthcare segment. These increases were partially offset by lower volumes for endodontic products and CAD/CAM products, and unfavorable pricing for implants and prosthetics products.

Gross Profit

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Gross profit $466 $506 $(40) (7.9%)
Gross profit as a percentage of net sales 53.0% 53.1% (10) bps

Percentages are based on actual values and may not reconcile due to rounding.

Gross profit as a percentage of net sales for the three months ended March 31, 2025 showed a slight decline as the unfavorable absorption on lower volumes, foreign currency translation, and unfavorable mix of endodontic, CAD/CAM, and implants products were mostly offset by the impact of the one-time benefits to revenue noted above and a decrease in warranty costs.

Operating Expenses

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Selling, general, and administrative expenses ("SG&A") $358 $415 $(57) (13.6%)
Research and development expenses ("R&D") 36 42 (6) (14.8%)
Intangible asset impairments — 6 (6) NM
Restructuring and other costs 9 1 8 NM
SG&A as a percentage of net sales 40.7% 43.5% (280) bps
R&D as a percentage of net sales 4.1% 4.4% (30) bps

Percentages are based on actual values and may not reconcile due to rounding.

NM - Not meaningful

SG&A Expenses

The decrease in SG&A expenses for the three months ended March 31, 2025 was primarily driven by lower headcount costs for Byte and lower sales and advertising costs for Byte products after the suspension of the sale and marketing of Byte aligner systems and impression kits announced in October 2024. The decrease was also due to lower headcount costs as a result of restructuring activities.

R&D Expenses

For the three months ended March 31, 2025, R&D expenses decreased as the Company continues to prioritize a disciplined approach with ongoing investments in digital workflow solutions, product development initiatives, and software development, including clinical application suite and cloud deployment. The Company expects to continue to maintain a level of investment in R&D that is at least 4% of annual net sales.

Goodwill and Intangible Asset Impairments

For the three months ended March 31, 2025, no goodwill or intangible asset impairment charges were recorded. For the three months ended March 31, 2024, the Company recorded an intangible asset impairment charge of $6 million. The charge was related to indefinite-lived imaging product trade names within the Connected Technology Solutions segment. For further information see Note 13, Goodwill and Intangible Assets, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Restructuring and Other Costs

For the three months ended March 31, 2025 and March 31, 2024, the Company recorded restructuring and other costs of $9 million and $1 million, respectively. The expenses in 2025 primarily consist of costs in connection with various restructuring initiatives. The expenses in 2024 consisted primarily of severance costs in conjunction with the restructuring plan announced in February 2023. For further details refer to Material Trends in Capital Resources below, and Note 8, Restructuring and other costs, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Segment Adjusted Operating Income

(in millions, except percentages)(a) Three Months Ended March 31, 2025 2024 $ Change % Change
Connected Technology Solutions $7 $2 $5 370.4%
Essential Dental Solutions 135 115 20 17.1%
Orthodontic and Implant Solutions 37 42 (5) (11.5%)
Wellspect Healthcare 26 23 3 14.2%

Percentages are based on actual values and may not reconcile due to rounding.

(a) See Note 6, Segment Information, in the Notes to Unaudited Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for a reconciliation from segment adjusted operating income to consolidated US GAAP income.

Connected Technology Solutions

The increase in segment adjusted operating income for the three months ended March 31, 2025 is due to improved margins primarily as a result of lower product warranty costs. The increase was partially offset by the lower organic sales noted above.

Essential Dental Solutions

The increase in segment adjusted operating income for the three months ended March 31, 2025 is due to lower headcount costs and professional service costs, favorable pricing particularly in Europe, and higher organic sales noted above.

Orthodontic and Implant Solutions

The decrease in segment adjusted operating income for the three months ended March 31, 2025 is due to the lower organic sales for direct-to-consumer aligners and implants and prosthetics products noted above. The decreases were partially offset by lower headcount costs and professional service costs, as well as an adjustment to net sales for estimated customer refunds for the Byte aligner business as noted above.

Wellspect Healthcare

The increase in segment adjusted operating income for the three months ended March 31, 2025 is due to the increase in organic sales noted above, as well as margin improvement due to the favorable manufacturing leverage from higher volumes.

Other Income and Expense

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change % Change
Interest expense, net $19 $18 $1 9.1%
Other (income) expense, net — (7) 7 NM
Net interest and other expense (income) $19 $11 $8

Percentages are based on actual values and may not reconcile due to rounding.

NM - Not meaningful

Interest expense, net

Interest expense, net for the three months ended March 31, 2025 increased compared to the three months ended March 31, 2024 primarily due to a higher average carrying balance of short-term borrowings.

Other (income) expense, net

Other (income) expense, net for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 is as follows:

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change
Foreign exchange gains $(2) $(9) $7
Defined benefit pension plan expenses 2 2 —
Other (income) expense, net $— $(7) $7

38

Income Taxes and Net Income

(in millions, except percentages)

Three Months Ended March 31, 2025 2024 $ Change
Provision for income taxes $25 $14 $11
Effective income tax rate 56.8% 44.9%
Net loss attributable to Dentsply Sirona $20 $18 $2
Diluted earnings per common share $0.10 $0.09

Percentages are based on actual values and may not reconcile due to rounding.

Provision for income taxes

The effective tax rates for the three months ended March 31, 2025 and 2024 were 56.8% and 44.9%, respectively. The increase in effective tax rate is primarily driven by additional valuation allowance recorded in the three months ended March 31, 2025.

CRITICAL ACCOUNTING ESTIMATES

Goodwill and Indefinite-Lived Intangible Assets

Goodwill represents the excess cost over the fair value of the identifiable net assets of business acquired and is allocated among the Company's reporting units. Indefinite-lived intangible assets consist of trade names, trademarks, and in-process R&D. Neither goodwill nor indefinite-lived intangible assets are amortized; instead, they are tested for impairment annually at April 1 or more frequently if events or circumstances indicate that the carrying value may be impaired, or if a decision is made to sell, discontinue, or divest a business. Judgment is involved in determining if an indicator of impairment has occurred during the year. Such indicators may include a decline in expected cash flows, unanticipated competition, increased interest rates, or slower growth rates, among others.

For the three months ended March 31, 2025, the Company considered qualitative and quantitative factors to determine whether any events or changes in circumstances had resulted in a more likely than not impairment of any of its goodwill or indefinite-lived intangible assets during the course of the quarter, and concluded there were no such indicators. As of March 31, 2025 the estimated fair value of the Implant & Prosthetic Solutions reporting unit within the Orthodontic and Implant Solutions segment exceeded its carrying value by less than 10%. The Company performed a hypothetical sensitivity analysis, based on the last impairment test performed as of December 31, 2024, by increasing the discount rate by 50 basis points. An increase of the discount rate by 50 basis points would result in a material impairment of the Implant & Prosthetic Solutions reporting unit, and therefore this reporting unit remains at-risk for future goodwill impairment. Additionally, the fair values of certain indefinite-lived intangible assets within the Orthodontic and Implant Solutions and Connected Technology Solutions segments continue to approximate carrying value. Any deviation in actual financial results compared to the forecasted financial results or valuation assumptions used in the annual or interim tests, a decline in equity valuations, increases in interest rates, or changes in the use of intangible assets, among other factors, could have a material adverse effect to the fair value of either the reporting units or intangible assets and could result in a future impairment charge. Goodwill associated with the Implant & Prosthetic Solutions reporting unit was $522 million at March 31, 2025, and the carrying values of the at-risk indefinite-lived intangible assets within the Orthodontic and Implant Solutions and Connected Technology Solutions segments were $83 million and $159 million, respectively, at March 31, 2025.

For further information see Note 13, Goodwill and Intangible Assets, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q, and Critical Accounting Estimates in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the 2024 Form 10-K.

LIQUIDITY AND CAPITAL RESOURCES

(in millions)

Cash (used in) provided by: Three Months Ended March 31, 2025 2024 $ Change
Operating activities $7 $25 $(18)
Investing activities (17) (43) 26
Financing activities 123 (14) 137
Effect of exchange rate changes on cash and cash equivalents 13 (11) 24
Net (decrease) increase in cash and cash equivalents $126 $(43) $169

40

Cash provided by operating activities decreased compared to the three months ended March 31, 2024, primarily as a result of changes in working capital, including higher accounts receivable due largely to timing of sales and customer remittances and higher build of inventory during the current period, partially offset by lower payments to vendors during the current period due to timing. At March 31, 2025, the number of days for sales outstanding in accounts receivable increased by 4 days to 59 days as compared to 55 days at December 31, 2024, and the number of days of sales in inventory increased by 8 days to 132 days at March 31, 2025 as compared to 124 days at December 31, 2024.

The cash used in investing activities decreased compared to the three months ended March 31, 2024, due to lower capital expenditures of $15 million and no cash paid on the settlement of derivatives, compared to $9 million paid for the interest rate swap closure in the prior year. The Company estimates capital expenditures to be in the range of approximately $160 million to $190 million for the full year 2025 and expects these investments to include expenses for the ongoing implementation of a new global Enterprise Resource Planning (“ERP”) system, equipment upgrades, and capacity expansion to support product innovation and consolidate operations for enhanced efficiencies.

On March 19, 2025, the Company entered into a 364-day term loan of $435 million with a maturity date of March 18, 2026 (the “Bridge Loan”). Borrowings under the Bridge Loan will bear interest at a fluctuating rate per annum equal to, at the Company’s option, (i) the forward-looking Secured Overnight Financing Rate (such borrowings, “Term Benchmark Loans”), or (ii) a base rate, plus, in each case, an applicable margin calculated based on the Company’s credit ratings from Moody’s Investors Service, Inc. and Standard & Poor’s Ratings Services at the time and, in the case of Term Benchmark Loans, an adjustment of 10 basis points. In the event that the Bridge Loan remains outstanding for more than 90, 180, or 270 days, the Company will be obligated to pay duration fees of 0.50%, 0.75% and 1.00%, respectively, of the principal amounts outstanding on such dates. The net proceeds were $432 million, net of issuance fees totaling $3 million. The proceeds are being used to repay borrowings under the commercial paper facility and for other general corporate purposes.

Cash provided by financing activities increased compared to the three months ended March 31, 2024 primarily as a result of the Company entering into the Bridge Loan. The increase in cash provided by financing activities was partially offset by repayments on the commercial paper facility.

On November 7, 2023, the Board of Directors approved an increase to the authorized share repurchase program of $1.0 billion. At March 31, 2025, the Company had $1.19 billion of authorization remaining available for share repurchases. Additional share repurchases, if any, may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions, or other transactions in such amounts and at such times as the Company considers appropriate based upon prevailing market and business conditions and other factors. The Company is restricted from making share repurchases during the duration of the Bridge Loan. At March 31, 2025, the Company held 65.2 million shares of treasury stock.

The Company's ratio of total net debt to total capitalization was as follows:

(in millions, except percentages)

March 31, 2025 December 31, 2024
Notes payable and current portion of debt $742 $549
Long-term debt 1,593 1,586
Less: Cash and cash equivalents 398 272
Net debt 1,937 1,863
Total equity 2,010 1,943
Total capitalization $3,947 $3,806
Total net debt to total capitalization ratio 49.1% 48.9%

At March 31, 2025, the Company had $584 million of borrowings available under lines of credit, including lines available under its short-term arrangements and revolving credit facility. The Company’s borrowing capacity includes a $700 million multi-currency credit facility which expires in May 2028. The Company also has access to an aggregate $700 million under a U.S. dollar commercial paper facility. The $700 million revolver serves as a back-up to the commercial paper facility, thus the total available credit under the commercial paper facility and the multi-currency revolving credit facility in the aggregate is

$700 million. The Company had $140 million outstanding borrowings under the commercial paper facility at March 31, 2025 resulting in $560 million remaining available under the revolving credit and commercial paper facilities. The Company also has access to $33 million in uncommitted short-term financing under lines of credit from various financial institutions, the availability of which is reduced by other short-term borrowings. The lines of credit have no major restrictions and are provided under demand notes between the Company and the lending institutions. At March 31, 2025, the Company had $9 million outstanding under short-term borrowing arrangements.

The Company’s revolving credit facility, term loans and senior notes contain certain covenants relating to the Company’s operations and financial condition. The most restrictive of these covenants are: (1) a ratio of total debt outstanding to total capital not to exceed 0.6, and (2) a ratio of operating income excluding depreciation and amortization to interest expense of not less than 3.0 times, in each case, as such terms are defined in the relevant agreement. Any breach of any such covenants would result in a default under the existing debt agreements that would permit the lenders to declare all borrowings under such debt agreements to be immediately due and payable and, through cross default provisions, would entitle the Company’s other lenders to accelerate their loans. At March 31, 2025, the Company was in compliance with these covenants.

The Company expects on an ongoing basis to be able to finance operating cash requirements, capital expenditures, and debt service from the current cash, cash equivalents, cash flows from operations and amounts available under its existing borrowing facilities. The Company’s credit facilities are further discussed in Note 12, Financing Arrangements, to the Unaudited Consolidated Financial Statements of this Form 10-Q.

The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries’ operating activities and future foreign investments. The Company has the ability to repatriate cash to the United States, which could result in an adjustment to the tax liability for foreign withholding taxes, foreign and/or U.S. state income taxes, and the impact of foreign currency movements. At March 31, 2025, management believed that sufficient liquidity was available in the United States and expects this to continue for the next twelve months. The Company has repatriated and expects to continue repatriating certain funds from its non-U.S. subsidiaries that are not needed to finance local operations. Repatriation activities both performed and contemplated to date have not resulted in, and are not expected to result in, any significant incremental tax liability to the Company.

The Company continues to review its debt portfolio and may refinance additional debt or add debt in the near-term based on strategic capital management. The Company believes there is sufficient liquidity available for the next twelve months.

Restructuring Plans

On July 29, 2024, the Board of Directors of the Company approved a plan to restructure the Company’s business to improve operational performance and drive stockholder value creation (the “2024 Plan”). In connection with the 2024 Plan, the Company anticipates a net reduction in the Company’s global workforce of approximately 2% to 4%. The Company anticipates that the 2024 Plan will be substantially completed by the end of 2025 and result in $80 million to $100 million in annual cost savings. The proposed changes are subject to co-determination processes with employee representative groups in countries where required.

As of March 31, 2025, in connection with the 2024 Plan, the Company has incurred $30 million in restructuring charges from inception, primarily related to employee transition, severance payments and employee benefits, which are expected to be expensed and paid in cash in 2024 and 2025. Actions taken under the 2024 Plan will seek to streamline the Company’s operations and global footprint, as well as improve alignment of the Company’s cost structure with its strategic growth objectives. In total, including the charges already incurred, the Company expects to incur between $35 million and $50 million in non-recurring restructuring charges under the 2024 Plan.

On February 14, 2023, the Board of Directors of the Company approved a plan to restructure the Company’s business through a new operating model with five global business units, optimize central functions and overall management infrastructure, and implement other efforts aimed at cost savings (the “2023 Plan”). The Company estimated a reduction in its global workforce of approximately 8% to 10% and annual cost savings of approximately $200 million pursuant to the 2023 Plan. The target for cost savings has been substantially met, with the benefits mostly offset in the short term by additional investments in sales personnel, the Company’s new global ERP system, and other transformation initiatives. During the course of 2023 and 2024, the Company incurred $86 million in restructuring charges in conjunction with the 2023 Plan, primarily related to employee transition, severance payments, employee benefits, and facility closure costs, and $20 million in other non-recurring costs related to restructuring activities which mostly consist of consulting, legal and other professional service fees. Remaining restructuring charges attributable to the 2023 Plan are not expected to be material.

The estimates of the charges and expenditures that the Company expects to incur in connection with the 2024 Plan, and the timing thereof, are subject to several assumptions, including local law requirements in various jurisdictions and co-determination aspects in countries where required. Actual amounts may differ materially from estimates. In addition, the Company may incur additional charges or cash expenditures not currently contemplated due to unanticipated events that may occur, including in connection with the implementation of the 2024 Plan. For further details refer to Note 8, Restructuring and Other Costs, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

NEW ACCOUNTING PRONOUNCEMENTS

Refer to Part I, Item 1, Note 1, Business and Basis of Presentation, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q for a discussion of recent accounting pronouncements.

Market risk

As filed, 171 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes from the information provided in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our 2024 Form 10-K.

Controls and procedures

As filed, 2,195 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer, who is also serving as the Company’s principal financial officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed or submitted under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that it is accumulated and communicated to management, including the Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

The Company has committed to a multi-year project to implement a new ERP system using a global platform. The implementation is underway and is expected to continue to occur in phases over the next several years. In connection with the ERP implementation, we are updating and will continue to update our internal control over financial reporting, as necessary, to accommodate modifications to our business processes and accounting procedures.

Except with respect to the continued implementations of the new ERP system, there have been no changes in our internal control over financial reporting during the three months ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We will continue to evaluate any further changes that could materially affect, or are reasonably likely to materially affect, our internal control over financial reporting over the course of the implementation of the new ERP system and other related systems.

Risk factors

As filed, 169 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes to the risk factors as disclosed in Part I, Item 1A, “Risk Factors” in the

Company’s Form 10-K for the year ended December 31, 2024.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-01-01 to 2025-03-31$879.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2025-01-01 to 2025-03-31$413.0mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2025-01-01 to 2025-03-31$466.0mus-gaap:GrossProfit
Research and development3 months2025-01-01 to 2025-03-31$36.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2025-01-01 to 2025-03-31$358.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-01-01 to 2025-03-31$63.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2025-01-01 to 2025-03-31$19.0mus-gaap:InterestExpenseNonoperating
Income tax3 months2025-01-01 to 2025-03-31$25.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-01-01 to 2025-03-31$20.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-01-01 to 2025-03-31$0.10us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-01-01 to 2025-03-31$0.10us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-01-01 to 2025-03-31199,800,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2025-01-01 to 2025-03-31$7.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2025-01-01 to 2025-03-31$19.0mus-gaap:PaymentsToAcquireProductiveAssets
Dividends paid3 months2025-01-01 to 2025-03-31$32.0mus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2025-03-31$398.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-03-31$1.98bnus-gaap:AssetsCurrent
Total assetsAt period end2025-03-31$6.05bnus-gaap:Assets
Current liabilitiesAt period end2025-03-31$1.79bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-03-31$4.04bnus-gaap:Liabilities
Long-term debtAt period end2025-03-31$1.59bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2025-03-31$742.0mus-gaap:DebtCurrent
Shareholders' equityAt period end2025-03-31$2.01bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000818479-25-000056. Last ingested by Listed: Nov 14, 2026, 19:27 ET. Listed shows no prices and gives no investment advice.